Table 3.
Univariate analysis of potential prognostic factors associated with hepatitis in HBsAg-negative DLBCL patients
| Factor | Without hepatitis [cases (%)] | With hepatitis [cases (%)] | P value |
|---|---|---|---|
| Total | 144 | 21 | |
| HBcAb | 0.013 | ||
| – | 101 (70.1) | 9 (42.9) | |
| + | 43 (29.9) | 12 (57.1) | |
| HBeAb | 1.000 | ||
| – | 131 (91.0) | 19 (90.5) | |
| + | 13 (9.0) | 2 (9.5) | |
| Age (years) | 0.399 | ||
| ≤60 | 62 (43.1) | 7 (33.3) | |
| >60 | 82 (56.9) | 14 (66.7) | |
| Sex | 0.756 | ||
| Female | 60 (41.7) | 8 (38.1) | |
| Male | 84 (58.3) | 13 (61.9) | |
| ECOG PS | 0.500 | ||
| 0–1 | 125 (86.8) | 17 (81.0) | |
| ≥2 | 19 (13.2) | 4 (19.0) | |
| B symptoms | 0.726 | ||
| − | 108 (75.0) | 15 (71.4) | |
| + | 36 (25.0) | 6 (28.6) | |
| Ann Arbor stage† | 0.129 | ||
| I–II | 73 (50.7) | 7 (33.3) | |
| III-IV | 70 (48.6) | 14 (66.7) | |
| Liver involvement | 0.598 | ||
| − | 136 (94.4) | 21 (100) | |
| + | 8 (5.6) | 0 (0) | |
| Spleen involvement | 1.000 | ||
| − | 131 (91.0) | 19 (90.5) | |
| + | 13 (9.0) | 2 (9.5) | |
| Involved extranodal sites | 0.586 | ||
| <2 | 111 (77.1) | 15 (71.4) | |
| ≥2 | 33 (22.9) | 6 (28.6) | |
| Bone marrow involvement | 1.000 | ||
| − | 134 (93.1) | 20 (95.2) | |
| + | 10 (6.9) | 1 (4.8) | |
| IPI score† | 0.180 | ||
| 0–1 | 63 (43.8) | 6 (28.6) | |
| 2–5 | 80 (55.8) | 15 (71.4) | |
| ALT | 0.013 | ||
| ≤40 U/L | 128 (88.9) | 14 (66.7) | |
| >40 U/L | 16 (11.1) | 7 (33.3) | |
| AST | 0.019 | ||
| ≤45 U/L | 131 (91.0) | 15 (71.4) | |
| >45 U/L | 13 (9.0) | 6 (28.6) | |
| TB | 0.696 | ||
| ≤20.5 μmol/L | 129 (89.6) | 20 (95.2) | |
| >20.5 μmol/L | 15 (10.4) | 1 (4.8) | |
| LDH | 0.728 | ||
| ≤245 U/mL | 88 (61.1) | 12 (57.1) | |
| >245 U/mL | 56 (38.9) | 9 (42.9) |
Footnotes as in Table 1.